From experimental design to quality by design in pharmaceutical legislation

Accreditation and Quality Assurance

Volumn 17, Issue 6, 2012, Pages 627-633

  Savic, Ivan M ^a   Marinkovic, Valentina D ^b   Tasic, Ljiljana ^b   Krajnovic, Dusanka ^b   Savic, Ivana M ^a  

^a UNIVERSITY OF NI   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Experimental design; Pharmaceutical legislation; Pharmaceutical quality system; Quality by design

Indexed keywords

EID: 84873266851     PISSN: 09491775     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00769-012-0926-y     Document Type: Review

References (32)

1. Juran JM (1992) Juran on quality by design: the new steps for planning quality into goods and services. The Free Press, USA.
2. Gibson M (2004) Pharmaceutical preformulation and formulation-a practical guide from candidate drug selection to commercial dosage form. United States of America.
3. Huang NE, Shen Z, Long SR, Wu MC, Shih EH, Zheng Q, Tung CC, Liu HH (1998) The empirical mode decomposition method and the Hilbert spectrum for non-stationary time series analysis. Proc R Soc Lond 454A: 903-995.
4. Savic I, Marinkovc V, Savic I, Sibinovic P, Cekic N (2012) Application of experimental design on photostability investigation of Karvileks tablet. Indian J Pharm Educ 46(3) (in press).
5. Savic I, Nikolic G, Savic I, Cakic M, Dosic A, Canadi J (2012) Modeling of bioactive copper(II) complex stability by use of experimental design. Chem Ind. doi: 10. 2298/HEMIND120120021S.
6. Savic I, Nikolic K, Nikolic G, Savic I, Agbaba D (2012) Application of mathematical modeling for the development and optimization formulation with bioactive copper complex. Drug Dev Ind Pharm (in press). doi: 10. 3109/03639045. 2012. 707208.
7. Kutle L, Pavlovic N, Dorotic M, Zadro I, Kapustic M, Halassy B (2010) Robustness testing of live attenuated rubella vaccine potency assay using fractional factorial design of experiments. Vaccine 28(33): 5497-5502.
8. Sungthongjeen S (2004) Application of Arrhenius equation and Plackett-Burman design to ascorbic acid syrup development. Naresuan Univ J 12: 1-12.
9. Li W, Rasmussen HT (2003) Strategy for developing and optimizing liquid chromatography methods in pharmaceutical development using computer-assisted screening and Plackett-Burman experimental design. J Chromatogr A 1016(2): 165-180.
10. Paterakis PG, Korakianiti ES, Dallas PP, Rekkas DM (2002) Evaluation and simultaneous optimization of some pellets characteristics using a 3(3) factorial design and the desirability function. Int J Pharm 248(1-2): 51-60.
11. Bodea A, Leucuta SE (1997) Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int J Pharm 154(1): 49-57.
12. Gohel MC, Amin AF (1998) Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release 51(2-3): 115-122.
13. Milenkovic M, Marinkovic V, Sibinovic P, Palic R, Milenovic D (2010) An HPLC method for the determination of digoxin in dissolution samples. J Serb Chem Soc 75: 1583-1594.
14. Marinkovic V, Karljikovic-Rajic K, Agbaba D, Nikolic M (2005) Experimental design as a quality improvement function. Total Qual Manag Excell 1-2: 193-195.
15. Barmpalexis P, Kanaze FI, Georgarakis E (2009) Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology. J Pharm Biomed Anal 49(5): 1192-1202.
16. Srinubabu G, Lokeswari N, Jayaraju K (2007) Screening of nutritional parameters for the production of protease from Aspergillus oryzae. E-J Chem 4: 208-215.
17. Bolourchian N, Hadidi N, Foroutan SM, Shafaghi B (2009) Development and optimization of a sublingual tablet formulation for physostigmine salicylate. Acta Pharm 59: 301-312.
18. Mura P, Furlanetto S, Cirri M, Maestrelli F, Marras AM, Pinzauti S (2005) Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. J Pharm Biomed Anal 37(1): 65-71.
19. Cafaggi S, Leardi R, Parodi B, Caviglioli G, Bignardi G (2003) An example of application of a mixture design with constraints to a pharmaceutical formulation. Chemom Intell Lab 65: 139-147.
20. Marti-Mestres G, Nielloud F, Marti R, Maillols H (1997) Optimization with experimental design of nonionic, anionic, and amphoteric surfactants in a mixed system. Drug Dev Ind Pharm 23: 993-998.
21. Vojnovic D, Chicco D (1997) Mixture experimental design applied to solubility predictions. Drug Dev Ind Pharm 23: 639-645.
22. http://www. ich. org/LOB/media/MEDIA4986. pdf.
23. PET Drugs-Current Good Manufacturing Practice (CGMP), U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2011). http://www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default. htm.
24. http://www. ich. org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline. pdf.
25. ICH Harmonised Tripartite Guideline, Development and Manufacture of Drug Substances (Chemical Entities And Biotechnological/Biological Entities) Q11, (2012).
26. Pharmaceutical quality system ICH Q 10, EMA/INS/GMP/79818 (2011).
27. Marinkovic V, Tasic LJ, Majstorovic V (2008) Risk management according the model of ISO 31000-pharmaceutical approach. Total Qual Manag Excell 36: 421-424.
28. Tasic LJ, Marinkovic V, Vecerkov-Vukmirovic S (2008) From technology transfer to process design-an approach of knowledge management in pharma business. Total Qual Manag Excell 36: 53-56.
29. Tasic LJ, Cvetovski A, Marinkovic V (2007) Knowledge management as a tool in pharma business. Total Qual Manag 35: 113-117.
30. Branning R, Torbeck L (2009) QbD: convincing the skeptics. Biopharm Int 22: 5-8.
31. PharmaQbD web cast (2008) http://www. pharmaqbd. com.
32. Marinkovic V, Vecerkov-Vukmirovic S, Tasic LJ, Majstrovic V (2009) Investigation of QM practice in pharmaceutical industry of Serbia. Total Qual Manag Excell 37: 133-137.